Asset profile
galvokimig
Multispecific antibody
Evidence outlook · lead readout
NCT04643457 · Atopic Dermatitis
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT04643457: The study randomized 107 participants and used quadruple blinding with placebo control. Its primary measures included treatment-emergent adverse events and the clinical EASI75 endpoint in the atopic dermatitis group, but no primary-endpoint results or statistical comparisons are posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
May 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access Research2029 (1)
June 2029 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.